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Mauldin et al. (2009) use NMR to show that drug binding can break up collective protein motions necessary
for function. We discuss their findings in the context of drug discovery in pharmaceutical research.Proteins are nanodevices designed by
molecular evolution. Critically, they are
devices with ‘‘moving parts’’—they
possess internal motions. While no one
doubts the existence of these motions,
defining their relevance to drug design
has been historically difficult. Are they
incidental or essential?
Nuclear magnetic resonance (NMR)
suggests the latter. NMR is unique in its
ability to profile the atomic motions of
bio-macromolecules on multiple time
scales, both comprehensively and nonin-
vasively (Palmer, 2004). As a result, it has
emerged as a premier tool for correlating
protein flexibility with function studies
(flexibility-function studies). NMR shows
clearly that proteins of therapeutic
interest use internal motions for binding,
catalysis, and signal transduction (Cheng
et al., 1994; Nicholson et al., 1995;
Eisenmesser et al., 2002; Boehr et al.,
2006; Namanja et al., 2007). One might
guess then that NMR flexibility-function
studies would be prevalent in pharmaceu-
tical research. Instead, flexibility-function
studies are rather rare events.
Why is this? We suggest some possible
reasons. Because chemical space is
vast and time is short, pharmaceuticalresearch is under enormous pressure to
push high-throughput methodologies.
However, NMR dynamics studies involve
recording numerous datasets at higher
signal-to-noise, owing to their quantita-
tive nature. Also, typical drug targets
have higher molecular weights that give
crowded NMR spectra and broad reso-
nances. Together, these factors promote
longer acquisition times and reduced
throughput. Another issue is that the
metrics of protein dynamics—order
parameters, exchange rates, and correla-
tion times—do not translate easily into
strategies for medicinal chemistry. This
contrasts with structural coordinates,
which seemingly lock each atom in place
and thereby dictate where one should
insert, optimize, or remove a ligand func-
tional group. Thus, the dynamics informa-
tion may not be used even if they are
acquired at high-throughput. Together,
the above issues discourage the practice
of flexibility-function studies in pharma-
ceutical research. In turn, this reinforces
old perceptions that protein motions are
small perturbations that can be, to the first
approximation, disregarded, and that
static models are sufficient for efficient
drug discovery.Structure 17, March 11, 2009In essence, there is a communication
breakdown between the information
available from flexibility-function studies
on the one hand, and the realities of phar-
maceutical research settings on the other.
Should there be concern? The new study
from Mauldin et al. (2009) answers with
a resounding ‘‘yes.’’
Specifically, Mauldin et al. (2009) used
acomprehensivearrayof 15Nand 2H(deute-
rium) NMR spin relaxation experiments to
investigate how the functional motions of
a classic enzyme drug target, dihydrofolate
reductase (DHFR), would respond to the
binding of two well-established DHFR
drugs: the anticancer agent, Methotrexate
(MTX), and the antibiotic Trimethoprim
(TMP). Accordingly, they profiled the
motionsofE.coliDHFRboundwithcofactor
NAPDH (the holoenzyme), in the presence
and absence of MTX and TMP.
For the holoenzyme, Mauldin et al.
(2009) applied backbone 15N relaxation
dispersion experiments and observed
the ms-ms collective motions of loops
surrounding the cofactor and substrate
binding pockets. These motions, previ-
ously identified by Boehr et al. (2006),
reflect the exchange between the
‘‘occluded’’ and ‘‘closed’’ conformers,ª2009 Elsevier Ltd All rights reserved 319
Structure
Previewsand are believed to gate the contact
between the bound NADPH cofactor and
substrate. Thus, these collective motions
are the ‘‘moving parts’’ underlying the
DHFR catalytic cycle.
Then they added the drugs. Remark-
ably, drug binding at the substrate site
eliminates conformational exchange for
remote residues at the co-factor (NADPH)
binding site. Exchange persists in the
substrate binding pocket, but at reduced
rate. Thus, drug binding breaks up the
original ms-ms collective loop motion of
the holoenzyme into smaller, unproduc-
tive clusters of local motion. Mauldin
et al. (2009) refer to this as ‘‘dynamic
dysfunction’’. Critically, both inhibitors
caused the same dysfunction, suggesting
these dynamic changes are indeed con-
nected to inhibition.
Drug binding also perturbs the ampli-
tudes of fast ps-ns motions for both back-
bone and methyl side chains. The
affected residues common to both drugs
trace an internal path that links the
substrate binding site to distal residues
known to be important for catalysis. This
phenomenon has been observed in other
proteins (Fuentes et al., 2004; Clarkson
et al., 2006; Namanja et al., 2007) and
may prove to be a prevalent mechanism
for intraprotein signaling between func-
tional sites.
Thus, the DHFR results point to
a broader way of envisioning inhibitor
design. MTX and TMP do not merely oust
substrate; rather, they cause a communi-
cation breakdown within the network of320 Structure 17, March 11, 2009 ª2009 Elscollective motions necessary for DHFR
catalysis. One wonders how many other
known drugs may act in a similar fashion.
The DHFR study highlights several
points relevant for drug discovery in
general. First, flexibility-function studies
can point to new modes of drug action
that would be invisible to traditional drug
design strategies that tend to focus on
structure alone. Second, we can broaden
our notion of drug action beyond the inhi-
bition of active sites to the inhibition of
functional dynamics. Of course, realizing
such inhibition would require that flexi-
bility-function studies become an integral
component of drug discovery efforts.
Third, protein functional motions can be
distributed among networks of residues
(Clarkson et al., 2006; Hammes-Schiffer
and Benkovic, 2006). Hence, motions at
one site can be inhibited by binding at
a remote site. While this introduces
some complexity, it also widens the range
of potential drug binding sites for making
selective inhibitors. Last, protein
dynamics studies should be comple-
mented by studies of the dynamics of its
corresponding ligand(s) (Peng, 2003;
Zintsmaster et al., 2008). Added insight
from the ligand perspective provides the
crucial link to iterative drug design, which,
after all, modifies the ligand, not the
protein.
The drug-induced communication
breakdown within DHFR should inspire us
to confront the communication breakdown
between flexibility-function studies and
drug discovery. Intrinsic protein motionsevier Ltd All rights reservedare potentially new targets of opportunity
for drug discovery. Realizing this potential
calls for dynamics research into other
protein systems and ligands. While such
research may be ill-suited to current high-
throughput environments, it may ultimately
be necessary, lest we overlook an entire
vista of new drug design possibilities.
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